Harvard Bioscience (HBIO) Depreciation & Amortization (CF) (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $443000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 1.77% year-over-year to $443000.0 in Q1 2026; TTM through Mar 2026 was $1.7 million, a 4.62% decrease from a year earlier, with the FY2025 full-year figure at $1.7 million, down 1.56% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $443000.0, up from $413000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for HBIO reached as high as $459000.0 in Q4 2024 and fell as low as $331000.0 in Q4 2022.
• Historically, Depreciation & Amortization (CF) has averaged $399764.7 across 5 years, with a median of $411000.0 in 2025.
• Across the five-year window, Depreciation & Amortization (CF) dropped 29.57% in 2022 and rose 28.61% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $331000.0 in 2022, then gained by 17.82% to $390000.0 in 2023, then increased by 17.69% to $459000.0 in 2024, then decreased by 10.02% to $413000.0 in 2025, then climbed by 7.26% to $443000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $443000.0 in Q1 2026, $413000.0 in Q4 2025, and $425000.0 in Q3 2025.